Hives and Angioedema

Urticaria (hives) and angioedema are related but mechanistically distinct entities that are often discussed together because they frequently co-occur. A wheal is a superficial, mast cell-driven swelling of the dermis — sharply circumscribed, almost invariably itchy, and fleeting, with each individual lesion typically resolving within 24 hours.^[1] Angioedema is a deeper swelling of the lower dermis, subcutaneous, or submucosal tissue that can occur together with wheals or entirely on its own, is often non-itchy (patients more commonly describe tingling, burning, tightness, or pain), resolves more slowly than a wheal, and — critically — can involve mucosal tissue such as the lips, tongue, and airway in a way that isolated urticaria does not.^[1] This distinction is the reason angioedema, unlike ordinary hives, carries a real risk of airway compromise, and it is also the reason this chapter exists: angioedema can arise from 2 fundamentally different mechanisms — mast cell/histamine-mediated (the "allergic" pathway) and bradykinin-mediated — that respond to completely different treatments, and mistaking one for the other is a genuine patient-safety failure.

This chapter is a companion to the Pharmasist Clinical Guidelines chapter on Chronic Urticaria, which covers the full assessment and the stepped, CSACI-endorsed pharmacotherapy ladder for hives lasting more than 6 weeks; that content is not repeated here. This chapter instead covers acute (under 6 weeks) urticaria briefly, then focuses on angioedema recognition — above all, ACE-inhibitor-induced angioedema and hereditary angioedema (HAE), the 2 classic bradykinin-mediated presentations a pharmacist must be able to recognize and distinguish from ordinary allergic swelling, since neither responds reliably to antihistamines, corticosteroids, or epinephrine.

Angioedema is a common reason for emergency evaluation, with roughly 1 in 3 to 1 in 4 presentations requiring hospital admission or observation.^[2] ACE inhibitors are the single leading drug-induced cause, responsible for an estimated 20% to 40% of angioedema-related emergency department visits, with an incidence of about 0.1% to 0.7% over the first 5 years of therapy — and symptoms begin within the first month of treatment in only about 10% of cases, meaning most episodes occur later, sometimes after years of uneventful use.^[3] Hereditary angioedema is far rarer, with an estimated combined prevalence of about 1 in 50,000 for its 2 main subtypes, but it carries a disproportionate share of angioedema mortality because of its unpredictable, recurrent, potentially laryngeal attacks.^[4]

Acute urticaria (brief overview)

Acute urticaria is the occurrence of wheals, angioedema, or both for 6 weeks or less, most often triggered by an infection, a food, or a medication, and it is typically self-limited.^[1] Routine diagnostic workup is not recommended unless the history points to a specific identifiable trigger.^[1] First-line management uses the same continuous, non-sedating second-generation H1-antihistamine backbone as chronic disease. See the Chronic Urticaria chapter for the complete, stepped pharmacotherapy ladder — updosing, then omalizumab, then cyclosporine — that applies once wheals or angioedema persist beyond 6 weeks; that ladder is not repeated here.

Angioedema: 2 mechanisms, 2 different clinical pictures

The single most important branch point in evaluating angioedema is whether it is mast cell/histamine-mediated or bradykinin-mediated, because the 2 pictures look different, arise from different causes, and are treated completely differently.^[2]

These distinguishing features — summarized from a comparative review of angioedema presentations in the emergency department^[2] — are the basis for the differentiation approach in Assessment & Diagnosis below. When mast cell-mediated angioedema occurs with systemic features (wheeze, hypotension, gastrointestinal symptoms), treat it as anaphylaxis; see the Anaphylaxis chapter for full management.

ACE-inhibitor-induced angioedema

ACE inhibitors reduce the breakdown of bradykinin (and substance P) by blocking the same enzyme that normally degrades it, so bradykinin accumulates and drives vasodilation and vascular leak.^[3] This can happen at any point during therapy, including after years of uneventful use — only about 10% of cases begin within the first month of starting the drug.^[3] Swelling characteristically develops over several hours and involves the face, lips, tongue, and upper airway, most often localized to the lips and tongue.^[3][2] There is no accompanying urticaria or itch — this is a key recognition point separating it from an allergic reaction — and gastrointestinal symptoms are uncommon, unlike hereditary angioedema, where they are common.^[3] Because the mechanism is not histamine-driven, ACE-inhibitor-induced angioedema does not reliably respond to epinephrine, antihistamines, or corticosteroids the way an allergic reaction does; management is primarily supportive, centred on airway protection, plus stopping the ACE inhibitor.^[3]

Hereditary angioedema (HAE)

HAE is a genetically inherited condition, almost always autosomal dominant, causing recurrent, unpredictable attacks of bradykinin-mediated swelling without urticaria.^[4] It is caused by deficient (HAE-1, about 85% of cases) or dysfunctional (HAE-2, about 15% of cases) C1-esterase inhibitor (C1-INH), a protein that normally restrains the bradykinin-generating pathway; a much rarer form has normal C1-INH function (HAE-nC1-INH).^[4] Attacks typically affect the extremities, face, genitals, bowel wall, and upper airway, and are often preceded by a prodrome such as fatigue or a non-itchy rash (erythema marginatum).^[4][2] Abdominal-pain crises from gastrointestinal-tract angioedema are common and can mimic a surgical abdomen — bowel-wall submucosal involvement occurs in up to 93% of HAE patients and can produce imaging findings (segmental bowel-wall edema, straightening of intestinal loops, ascites) that mimic obstruction.^[2] Roughly 3 in 4 patients have a positive family history; the remainder, up to about 25%, arise from a new (de novo) genetic variant, so a negative family history does not rule HAE out.^[4] The mean age of first attack is around 10 years, though onset ranges widely and symptoms may first appear in adulthood.^[4] Because HAE does not respond to standard allergy treatment, it requires specific on-demand therapies — C1-inhibitor concentrate, icatibant, or (where available) ecallantide — that are fundamentally different from anaphylaxis or allergic-angioedema management, plus prophylactic options for patients with frequent attacks; see Pharmacologic Treatment Options and Drug Tables.^[4]

Mast cell/histamine-mediated urticaria and angioedema

• A known food, drug, latex, or insect-venom allergy, or a history of physical/inducible urticaria triggers (cold, pressure, exercise, heat) — see the Anaphylaxis and Chronic Urticaria chapters for the full trigger lists.
• Concurrent NSAID use can aggravate mast cell-mediated urticaria/angioedema in a subset of patients.

ACE-inhibitor-induced angioedema

• Black or African-ancestry patients — risk is approximately 5-fold higher than in White patients, independent of ACE-inhibitor dose or other concurrent medications.^[3]
• Concomitant use of a dipeptidyl peptidase-4 (DPP-4) inhibitor/gliptin (e.g., sitagliptin), an mTOR inhibitor (e.g., sirolimus), or a neprilysin inhibitor (e.g., sacubitril, as in sacubitril/valsartan) — each further impairs bradykinin degradation or clearance.^[3]
• Concurrent NSAID or statin use, which can exacerbate ACE-inhibitor-induced angioedema.^[3]
• Female sex, older age, smoking, and a history of drug rash or seasonal allergies.^[2]
• No protective effect from having tolerated the drug for years — the rate of angioedema is highest in the first 30 days, but the risk persists for the entire duration of therapy, with documented cases after multiple years of uneventful use.^[2]
• Continuing the ACE inhibitor after a first episode: more than 40% of patients experience a recurrence, usually within the first month, and recurrent episodes can be more severe.^[3]

Hereditary angioedema

• A first-degree relative with HAE, or a family pattern of recurrent, unexplained swelling episodes — present in roughly 75% of cases; a de novo variant with no family history accounts for the rest.^[4]
• Estrogen-containing oral contraceptives or hormone therapy, and pregnancy, can trigger or increase the frequency of attacks in patients who already have HAE, though the effect is unpredictable and varies between patients and even between pregnancies in the same patient.^[4]
• Physical trauma, including medical/dental procedures and especially upper-airway manipulation (e.g., intubation, dental surgery), which can precipitate an attack, sometimes with a delay of hours to several days.^[4]
• Emotional stress is a commonly reported, though not rigorously proven, trigger.^[4]
• ACE inhibitors, DPP-4 inhibitors, and neprilysin inhibitors do not only cause angioedema on their own — they can also trigger attacks in patients who already have HAE, and should be avoided in known or suspected HAE regardless of the reason they might otherwise be prescribed.^[4]

History

Ask specifically: does the swelling come with itchy hives, or is it isolated? How quickly did it develop, and how long does it typically last? Has this happened before, and is there a family history of similar swelling or of early/unexplained death? Review the complete medication list for an ACE inhibitor, an ARB, a DPP-4 inhibitor/gliptin, an mTOR inhibitor, a neprilysin inhibitor, an estrogen-containing product, and NSAID use.^[3][4] Ask about recurrent, unexplained abdominal-pain episodes, which can be the dominant or only feature of HAE and are easily mistaken for another gastrointestinal or surgical diagnosis, particularly in children.^[4][2]

Physical examination and airway assessment

Assess vital signs and the airway first, before anything else — asphyxiation is the leading cause of death in angioedema of any cause.^[2] Look specifically for tongue, floor-of-mouth, or soft-palate swelling, and listen for stridor, hoarseness, or voice change. A patient who can phonate a high-pitched "E" without difficulty is unlikely to have significant laryngeal edema, though this is a supportive sign only and does not replace direct visualization when there is real concern.^[2] Findings limited to structures anterior to the teeth (isolated lip swelling) are lower risk than tongue, floor-of-mouth, or laryngeal involvement.^[2]

Investigations

Angioedema itself is a clinical diagnosis — no test is required in the acute setting to decide on airway management, and specialized testing should not delay treatment or disposition decisions.^[2] When the mechanism is unclear or HAE is suspected, the following tests help confirm the cause, best interpreted with or after discussion with allergy/immunology:

C1-INH levels are physiologically low in healthy newborns and can be transiently low in normal pregnancy, so results in infants under 12 months old and in pregnancy should be interpreted cautiously and confirmed after the first year of life or postpartum, respectively.^[4] Genetic testing can help when an affected parent's specific variant is already known, particularly in young children where biochemical testing is less reliable.^[4] Do not delay HAE-specific on-demand treatment of a significant attack while awaiting confirmatory laboratory results if the clinical picture is convincing.^[4]

A practical differentiation tool

One retrospective emergency department study proposed a simple bedside score to flag likely bradykinin-mediated angioedema: 1 point each for age over 65, dyspnea, absence of itching or erythema, laryngeal involvement, and use of an ACE inhibitor or ARB, plus 2 points if there was no response to corticosteroid therapy. A score of 3 or more identified bradykinin-mediated angioedema with 96% sensitivity and 84% specificity in that cohort, though the tool requires further validation before routine use and should support, not replace, clinical judgment.^[2]

Differential diagnosis

• Protect the airway — this goal comes before, and is independent of, determining the mechanism. Any tongue, laryngeal, or pharyngeal involvement, or voice/breathing change, is managed as a potential airway emergency first.^[2]
• For mast cell/histamine-mediated angioedema (with or without accompanying anaphylaxis features): reverse the reaction with epinephrine when anaphylaxis criteria are met, and control cutaneous symptoms with antihistamines/corticosteroids as adjuncts — see the Anaphylaxis chapter.
• For ACE-inhibitor-induced angioedema: remove the causative drug permanently, support the airway and vital signs until the episode resolves on its own (typically within 48-72 hours of stopping the drug), and prevent recurrence through class-wide avoidance and clear documentation.^[3]
• For hereditary angioedema: treat attacks early and specifically with on-demand therapy to shorten their duration and severity — earlier treatment produces a faster, more complete response^[4] — and, for patients with frequent or severe attacks, reduce future attack frequency/severity with short-term (peri-procedural) or long-term prophylaxis.
• Across all mechanisms: reach an accurate diagnosis, since the specific cause determines the entire treatment plan, and undiagnosed bradykinin-mediated angioedema (particularly HAE) carries a materially higher risk of a fatal outcome than diagnosed, appropriately managed disease.^[4]

• Airway-first positioning and preparation: keep any patient with tongue/laryngeal/pharyngeal involvement, stridor, or voice change under continuous observation with airway equipment and expertise readily available; avoid unnecessary manipulation of the airway and avoid supraglottic/extraglottic rescue devices, which sit above the obstruction and will not relieve bradykinin-mediated swelling.^[2]
• Remove/discontinue the causative drug: stop an ACE inhibitor permanently at the first confirmed or strongly suspected episode, and avoid re-challenging with any other ACE inhibitor.^[3] In known or suspected HAE, review for and discontinue any avoidable trigger drug — estrogen-containing contraceptives/hormone therapy, ACE inhibitors, DPP-4 inhibitors, and neprilysin inhibitors.^[4]
• HAE self-management: patients with a confirmed HAE diagnosis should be trained by an allergy/immunology team to self-administer their on-demand therapy so treatment is not delayed by access barriers, since delayed treatment is associated with slower, less complete resolution.^[4]
• Short-term (peri-procedural) prophylaxis: consider for HAE patients before a procedure carrying a meaningful trauma/airway-manipulation risk, particularly dental work, upper endoscopy, or intubation; counsel every HAE patient — even those who received prophylaxis — that an attack can still occur up to about 72 hours after a procedure.^[4]
• Medical-alert identification and a written action plan for confirmed HAE patients, covering how to recognize an attack, when and how to self-administer on-demand therapy, and when to seek emergency care regardless of self-treatment.
• Avoidance counselling and documentation: for any patient who has had ACE-inhibitor-induced or hereditary angioedema, ensure the reaction is clearly flagged in the medication/allergy record so it is not missed at a future prescribing decision.

Pregnancy

Children

HAE can present at any age, but the reported age of first attack ranges from about 4 to 18 years, with a mean around 10 years; presentation in infancy is uncommon, and abdominal symptoms are easily mistaken for other, more common childhood causes of abdominal pain.^[4] Weight-based dosing applies for on-demand therapy: plasma-derived C1-inhibitor (dosing varies by product and weight band), icatibant 0.4 mg/kg (max 30 mg) from 2 years of age in Canada, and recombinant C1-inhibitor or ecallantide from adolescence depending on the product and jurisdiction.^[4] Prophylactic agents (lanadelumab, subcutaneous C1-inhibitor) are generally licensed only from 12 years of age — younger children with frequent attacks need individualized specialist planning.^[4]

Older adults

Age itself is one of the factors used to flag likely bradykinin-mediated angioedema (over 65 years in the differentiation score above), and older adults are also disproportionately likely to be on an ACE inhibitor for cardiovascular or renal indications — maintain a high index of suspicion rather than assuming a first episode of angioedema late in life must be new-onset allergy.^[2]

Black and African-ancestry patients

The risk of ACE-inhibitor-induced angioedema is approximately 5-fold higher in Black patients than in White patients, independent of dose or other concurrent medications, likely reflecting genetic variation in bradykinin metabolism and handling.^[3] This should inform counselling when an ACE inhibitor is started and should heighten suspicion if unexplained facial or oral swelling develops in this population, however long the drug has been used without incident.

Patients who need continued renin-angiotensin-aldosterone system blockade

An angiotensin receptor blocker (ARB) acts on the renin-angiotensin system without inhibiting bradykinin breakdown, and Canadian genetic-association data indicate ARBs do not meaningfully increase angioedema recurrence risk in patients previously affected by ACE-inhibitor-induced angioedema, so an ARB can generally be used if RAAS blockade is still clinically indicated.^[3] That said, ARBs have themselves rarely been reported to cause angioedema through a distinct, less well-understood mechanism, so the cross-reactivity risk with a prior ACE-inhibitor reaction is low but not zero — counsel any patient switched to an ARB on angioedema recognition and give clear instructions to seek care promptly if swelling recurs.^[2][3]

1. Angioedema with airway involvement not improving, or worsening, despite initial management at any point: escalate immediately to advanced airway management (fiberoptic/video laryngoscopy) with preparation in parallel for a surgical airway — do not wait for a treatment response before preparing for this.^[2]
2. Presumed mast cell-mediated angioedema not responding to epinephrine/antihistamines/corticosteroids as expected: reconsider the diagnosis — this pattern should prompt a bradykinin-mediated workup (medication review, C4/C1-inhibitor testing) rather than simply repeating or escalating allergy-directed treatment.^[2]
3. Confirmed ACE-inhibitor-induced angioedema not improving with supportive care and drug discontinuation, particularly with ongoing airway threat: consider C1-inhibitor concentrate or fresh frozen plasma under specialist guidance, understanding the evidence for either is case-report level only, not trial-proven, for this specific indication.^[3]
4. HAE attack not responding to a first on-demand dose: reassess the airway and repeat/escalate on-demand therapy per the specific agent's guidance and specialist advice; do not assume the diagnosis is wrong simply because the first dose did not fully resolve symptoms, but do reassess for an alternative, less likely cause if the picture is atypical.
5. Frequent breakthrough attacks despite long-term prophylaxis: refer back to allergy/immunology for dose optimization, an alternative prophylactic agent, or reinforced trigger-avoidance and short-term prophylaxis planning around anticipated procedures.
6. Recurrent, unexplained angioedema or abdominal-pain episodes with a persistently normal basic workup: keep HAE-nC1-INH (normal C1-inhibitor) on the differential in specialist care — biochemical testing can be normal in this subtype, and diagnosis relies more heavily on clinical pattern, family history, and genetic testing where available.^[4]

• Treating ACE-inhibitor-induced or hereditary angioedema with epinephrine, antihistamines, or corticosteroids and expecting the response seen in an allergic reaction — none of these reliably works for a bradykinin-mediated mechanism.^[3][4]
• Assuming a patient who has tolerated an ACE inhibitor for years cannot be having ACE-inhibitor-induced angioedema now — onset can occur at any point in therapy, and only about 10% of cases begin in the first month.^[3]
• Switching a patient with confirmed ACE-inhibitor-induced angioedema to a different ACE inhibitor instead of the entire class.^[3]
• Refusing to ever use an ARB after prior ACE-inhibitor angioedema when RAAS blockade is genuinely needed — the risk is low, not zero, and should be discussed and monitored rather than treated as an absolute contraindication.^[3][2]
• Missing HAE because urticaria is absent and the swelling is assumed to be "not allergic, so not serious" — the absence of urticaria is actually a key positive clue toward a bradykinin-mediated process, not a reason to downgrade concern.^[4]
• Working up recurrent, unexplained abdominal pain purely as a gastrointestinal or surgical problem without asking about a family history of angioedema or prior swelling episodes, when HAE abdominal attacks are a recognized and common presentation.^[4][2]
• Using a supraglottic/extraglottic airway device, or unnecessary airway manipulation, in significant angioedema — both can worsen swelling, and neither relieves an obstruction that sits above the device.^[2]
• Delaying HAE-specific on-demand therapy while awaiting confirmatory C4/C1-inhibitor testing in a patient with a convincing clinical picture — early treatment improves outcomes, and testing should not gate treatment of a significant attack.^[4]
• Treating every episode of angioedema as a single generic entity rather than actively asking whether urticaria/itch is present and reviewing the medication list — this single branch point is what actually determines safe, effective management.

Mast Cell/Histamine-Mediated Angioedema — Emergency/Adjunct Therapy

For angioedema WITH accompanying urticaria/itch, or with anaphylaxis features. See the Anaphylaxis and Chronic Urticaria chapters for complete dosing, updosing, and the full stepped ladder — this row set is a cross-reference only, not a substitute for those chapters.

C1-Esterase Inhibitor Replacement — On-Demand Hereditary Angioedema Therapy

Give as early as possible in a confirmed or strongly suspected HAE attack. Reported (case-report level only) to shorten ACE-inhibitor-induced angioedema in some cases, but not supported by randomized trial evidence for that indication.

Bradykinin-Pathway Blockers — On-Demand Hereditary Angioedema Therapy

Randomized trials do NOT support these agents for ACE-inhibitor-induced angioedema — reserve them for confirmed or strongly suspected hereditary angioedema.

Long-Term and Short-Term Prophylaxis — Hereditary Angioedema, Specialist-Initiated

Reserve for patients with frequent or severe attacks (long-term) or an anticipated high-risk trigger such as a procedure (short-term). Initiate and monitor under allergy/immunology supervision.

Last-Resort Option

Use only when the therapies above are genuinely unavailable — this is not a preferred option for either hereditary or ACE-inhibitor-induced angioedema.